Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Start-Up Spotlight: ManRos Therapeutics

Posted on February 24th, 2017 by

Pharma R&D


This week we turn our attention to the busy start-up ManRos Therapeutics, based in France. Laurent Meijer, CEO & CSO of ManRos, details the company’s efforts to address several unmet medical needs.

Continue reading “Start-Up Spotlight: ManRos Therapeutics” »

Debates on Pharmacovigilance – What’s new and trending

Posted on February 22nd, 2017 by


Joyce D

Fleming’s Pharmacovigilance & Risk Management Strategies Forum is always an excellently organized event, attended by industry leaders, policy makers and legislators. It’s a superb opportunity to meet colleagues, make new connections, and discuss the challenges of PV and risk management Continue reading “Debates on Pharmacovigilance – What’s new and trending” »

How We Measure Success and Impact

Posted on February 20th, 2017 by

Pharma R&D


The start of the year is usually a period of reflection on what I achieved last year and what to focus on in the months ahead. It is also a time when we can receive feedback from our peers and stakeholders.  Continue reading “How We Measure Success and Impact” »

Start-Up Spotlight: StemCiTerra, LLC

Posted on February 17th, 2017 by

Pharma R&D

Stem cells

StemCiTerra, LLC is a small American start-up with a mission to make cancer treatments more effective. The company’s President & CSO, Lyubov Ostrovska, Ph.D., chats about their research. Continue reading “Start-Up Spotlight: StemCiTerra, LLC” »

Inside the Incubators of Innovation

Posted on February 15th, 2017 by

Pharma R&D

arctic pharma logo

2017 is well under way, and Arctic Pharma has big plans for the year. For one thing, we will be focused on submitting our provisional patents. We will also be working on performing toxicology studies on our best compounds. Continue reading “Inside the Incubators of Innovation” »

The Art of CAPA Writing

Posted on February 13th, 2017 by



Corrective and Preventive Actions (CAPAs) are a fundamental element of correcting deviation compliance in a regulated and quality Pharmacovigilance environment. Continue reading “The Art of CAPA Writing” »

  1. 1
  2. 2
  3. 3
  4. …
  5. 32

About this Blog


The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.

R&D Solutions for Pharma & Life Sciences

We're happy to discuss your needs and show you how Elsevier's Solutions can help.

Contact Sales